

## Liste der bewilligten Forschungsprojekte 2024 *Liste des projets de recherche acceptés en 2024*

Im [Forschungsportal](#) finden Sie Informationen zu allen Projekten, die die Stiftung Krebsforschung Schweiz und ihre Partnerorganisation Krebsliga Schweiz seit dem Jahr 2005 gefördert haben.

*Dans le [portail de recherche](#), vous trouverez les informations sur tous les projets soutenus par la fondation Recherche suisse contre le cancer et son organisation partenaire, la Ligue suisse contre le cancer, depuis 2005.*

### Basic research

**Arnold Isabelle** | Exploring eosinophil function in progressive colorectal cancer stages and metastasis in the era of transcriptomics

*Institute of Experimental Immunology, Universität Zürich (UZH), Zurich*

CHF 369 644 | 36 months | [KFS-6248-08-2024](#)

**Basler Konrad** | Investigating the similarities and differences between left- and right-sided colon cancer: a metastasis focus

*Institut für Molekulare Biologie, Universität Zürich (UZH), Zürich*

CHF 207 500 | 18 months | [KFS-6031-02-2024](#)

**Becher Burkhard** | Targeting IL-23R on tumour-infiltrating Tregs for cancer immunotherapy

*Institute of Experimental Immunology, Universität Zürich (UZH), Zürich*

CHF 351 578 | 36 months | [KFS-6022-02-2024](#)

**Beerenwinkel Niko** | Profiling tumour evolution in ovarian cancer for precision oncology

*Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule (ETH), Basel*

CHF 373 051 | 36 months | [KFS-6058-02-2024](#)

**Cejka Petr** | Towards mechanistic understanding of secondary DNA structure processing underlying synthetic lethality in cancer therapy

*USI, Istituto di Ricerca in Biomedicina (IRB), Bellinzona*

CHF 369 060 | 36 months | [KFS-6136-08-2024](#)

**Coukos George** | Laboratory evolution of cell states for next generation T cell cancer immunotherapy

*Department of Oncology, Centre hospitalier universitaire vaudois (CHUV), Lausanne*

CHF 358 143 | 48 months | [KFS-6060-02-2024](#)

- De Palma Michele** | Rewiring lung cancer immunity with engineered dendritic cell progenitors  
*Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne*  
CHF 366 980 | 48 months | [KFS-6045-02-2024](#)
- Fernandez Gonzalez Santiago** | Influence of the lymphatic versus hematogenous dissemination of B cell lymphoma in the immune response  
*Infection and Immunity, Istituto di Ricerca in Biomedicina (IRB), Bellinzona*  
CHF 346 738 | 48 months | [KFS-6092-02-2024](#)
- Gönczy Pierre** | Uncovering centriole number control mechanisms in health and cancer  
*SV ISREC UPGON, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne 15*  
CHF 373 980 | 36 months | [KFS-6018-02-2024](#)
- Hess Christoph** | Defining the metabolic and non-metabolic roles of QPRT in EBV-driven B cell lymphoma  
*Departement Biomedizin (DBM), Universität Basel, Basel*  
CHF 374 535 | 36 months | [KFS-6254-08-2024](#)
- Janscak Pavel** | Revisiting the molecular mechanisms underlying DNA replication stress induced by the chemotherapeutic agents cisplatin and mitomycin C  
*Institut für Molekulare Krebsforschung (Doppelinstitut MeF/MNF) (IMCR), Universität Zürich (UZH), Zürich*  
CHF 249 852 | 24 months | [KFS-6145-08-2024](#)
- Jourdain Alexis** | Blocking nucleoside catabolism to starve tumours  
*Immunobiology (formerly Biochemistry), Université de Lausanne (UNIL), Epalinges*  
CHF 375 000 | 48 months | [KFS-6029-02-2024](#)
- Marti Thomas** | Repurposing of the anti-epileptic drug stiripentol for cancer therapy  
*Clinic of Thoracic Surgery, Inselspital Bern, Bern*  
CHF 371 250 | 36 months | [KFS-6228-08-2024](#)
- Nombela Arrieta Cesar** | Inflammation-driven remodeling of the bone marrow microenvironment in the pathogenesis of acute myeloid leukemia  
*Medical Oncology and Hematology, Universität Zürich (UZH), Zürich*  
CHF 374 656 | 48 months | [KFS-6235-08-2024](#)
- Pruschy Martin** | Impact of draining lymph node irradiation during radioimmunotherapy on tumour dissemination  
*Departement für Radio-Onkologie, Universitätsspital Zürich (USZ), Zürich*  
CHF 249 240 | 24 months | [KFS-6223-08-2024](#)
- Riek Roland** | A new strategy to treat MAPK inhibitor resistant melanomas using the amyloid fold  
*Departement Chemie und Angewandte Biowissenschaften (D-CHAB), Eidgenössische Technische Hochschule (ETH), Zürich*  
CHF 374 640 | 48 months | [KFS-6068-02-2024](#)
- Stucki Manuel** | Targeting mitotic DNA damage tolerance pathways as a strategy to treat BRCA1/2-deficient cancers  
*Department of Gynecology, Universitätsspital Zürich (USZ), Schlieren*  
CHF 299 439 | 36 months | [KFS-6185-08-2024](#)

**Tamburini Jerome** | Targeting iron metabolism to eliminate quiescent leukemic stem cells in acute myeloid leukaemia

*Medical specialities, Université de Genève (UNIGE), Genève*

CHF 369 619 | 36 months | [KFS-6032-02-2024](#)

**Theurillat Jean-Philippe** | Understanding and co-targeting FOXA1 & FOXA2 in prostate cancer progression

*Institute of Oncology Research, Institute of Oncology Research (IOR), Bellinzona*

CHF 368 532 | 36 months | [KFS-6178-08-2024](#)

**Weller Michael** | Vortioxetine against glioblastoma: drug repurposing meets cancer neuroscience

*Department of Neurology and Laboratory of Molecular Neurooncology, Universitätsspital Zürich (USZ), Zurich*

CHF 341 833 | 36 months | [KFS-6084-02-2024](#)

**Zavolan Mihaela** | Discovery and functional characterization of HCC-associated small peptides

*Biozentrum, Universität Basel, Basel*

CHF 371 379 | 36 months | [KFS-6181-08-2024](#)

## Clinical Research – laboratory-oriented

**Bertholet Jenny** | Simultaneous optimization of radiation therapy in space and time: a new horizon for Temporally Feathered Radiation Therapy (TFRT)

*Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital Bern, Bern*

CHF 249 826 | 48 months | [KFS-6163-08-2024](#)

**Latorre Daniela** | The immune cells in checkpoint inhibitor-associated neuromuscular inflammation - dissecting potential therapeutic targets

*D-Biol, Eidgenössische Technische Hochschule (ETH), Zurich*

CHF 364 265 | 36 months | [KFS-6205-08-2024](#)

**Moeckli Raphaël** | FLIRT: FLASH irradiation treatment planning to facilitate and optimize glioblastoma treatments with very-high energy electron FLASH radiation therapy

*Institut de Radiophysique, Centre hospitalier universitaire vaudois (CHUV), Lausanne*

CHF 251 143 | 48 months | [KFS-6020-02-2024](#)

**Perentes Jean Yannis** | Understanding how the immunogenic cell death caused by hyperthermic intrathoracic cisplatin chemotherapy improves the control of malignant pleural disease alone or in combination with immunotherapy

*Service de chirurgie thoracique, Centre hospitalier universitaire vaudois (CHUV), Lausanne*

CHF 322 614 | 36 months | [KFS-6215-08-2024](#)

**Silina Karina** | Identification of survival-relevant immunological features in lung cancer

*Department of Chemistry and Applied Biosciences, Eidgenössische Technische Hochschule (ETH), Zurich*

CHF 312 500 | 30 months | [KFS-6108-02-2024](#)

**Vassella Erik** | Overcoming resistance to temozolomide and immunotherapy by targeting the nonsense-mediated mRNA decay pathway in glioblastoma tumours  
*Institute of Tissue Medicine and Pathology, Universität Bern (UniBE), Bern*  
CHF 349 842 | 48 months | [KFS-6061-02-2024](#)

**Wirsching Hans-Georg** | Radiation-associated meningioma molecular profiling to inform targeted therapies (RAMPIT)  
*Neurology, UniversitätsSpital Zürich (USZ), Zürich*  
CHF 371 188 | 48 months | [KFS-6103-02-2024](#)

**Zippelius Alfred** | Unravelling the relevance of intratumoral NK cell subtypes in lung cancer using multimodal single cell and spatial analysis  
*Medical Oncology, Laboratory Cancer Immunology, Department Biomedicine, Universitätsspital Basel (USB), Basel*  
CHF 304 265 | 24 months | [KFS-6233-08-2024](#)

## Clinical Research – patient-oriented

**Bösch Maximilian** | Fibre-Boost: A multicentre, 2:1 randomized, controlled trial to study the effects of a high-fibre dietary intervention on ctDNA clearance and the microbial and immunological landscape in immune checkpoint blockade-treated advanced non-small cell lung cancer  
*Lung Center, Kantonsspital St. Gallen (KSSG), St.Gallen*  
CHF 374 950 | 36 months | [KFS-6039-02-2024](#)

**Gotta Verena** | Prospective pharmacologic characterization of a novel cytomegalovirus-infection prophylaxis (Letermovir) in paediatric hematopoietic cell transplantation patients using endogenous Coproporphyrin (LetPeCo)  
*Pädiatrische Klinische Pharmazie / Pediatric Pharmacology and Pharmacometrics, Universitäts-Kinderspital beider Basel (UKBB), Basel*  
CHF 167 580 | 42 months | [KFS-6041-02-2024](#)

**Heinzelmann-Schwarz Viola** | Continuation of MATAO-Trial “Maintenance therapy with aromatase inhibitor in epithelial ovarian cancer: a phase III randomized double-blind placebo-controlled trial”  
*Gynecological Oncology, Universitätsspital Basel (USB), Basel*  
CHF 357 846 | 36 months | [KFS-6066-02-2024](#)

**Petignat Patrick** | Validation of AI-assisted digital telecytology for the triage of HPV-positive women in a same-day ‘Test-triage-treat’ strategy in Cameroon  
*Unité d'oncogynécologie chirurgicale, Université de Genève (UNIGE), Genève*  
CHF 375 000 | 36 months | [KFS-6044-02-2024](#)

**Toso Christian** | Assessing the impact of surgery on the immunity against hepatocellular carcinoma and on the use of immune check point inhibitors  
*Université de Genève (UNIGE)*  
CHF 370 517 | 36 months | [KFS-6186-08-2024](#)

**Weber Walter Paul** | Tailored axillary surgery de-escalation in patients with clinically node-positive breast cancer

*Surgery, Universitätsspital Basel (USB), Basel*

CHF 371 190 | 36 months | [KFS-6184-08-2024](#)

**Wenning Anna Silvia** | TOPANC Trial: Survival after TOtal versus partial PANCreaticoduodenectomy for adenocarcinoma of the pancreatic head, distal cholangiocarcinoma and ampullary cancer: a prospective multi-centric randomized controlled trial

*Department for Visceral Surgery and Medicine, Inselspital Bern, Bern*

CHF 365 960 | 48 months | [KFS-6043-02-2024](#)

**Zilli Thomas** | STAMPEDE2: A randomised controlled platform trial testing treatments in metastatic hormone sensitive prostate cancer - SABR Comparison S

*Radiation Oncology, Ente Ospedaliero Cantonale (EOC), Bellinzona*

CHF 373 151 | 48 months | [KFS-6158-08-2024](#)

## Epidemiological research

**Katapodi Maria** | CASCADE III: Designing risk-stratified models of survivorship care for HBOC and Lynch syndrome families

*Clinical Research, Faculty of Medicine, Universität Basel, Basel*

CHF 374 999 | 36 months | [KFS-6088-02-2024](#)

**Rothermundt Christian** | Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)

*Bereich Onkologie / Hämatologie, Kantonsspital St. Gallen (KSSG), St.Gallen*

CHF 217 760 | 48 months | [KFS-6034-02-2024](#)

**Schaffar Robin** | Cancer risk and prognosis among Individuals with Incarceration Experience: A Comprehensive Study in Geneva, Switzerland

*Registre Genevois des Tumeurs, Université de Genève (UNIGE), Genève*

CHF 157 338 | 24 months | [KFS-6201-08-2024](#)

**Schindera Christina** | Prospective multicentre cohort study of cardiac dysfunction in childhood cancer survivors: extension of the CardioOnco Study

*University Children's Hospital Basel, Universität Basel, Basel*

CHF 374 409 | 36 months | [KFS-6096-02-2024](#)

**Spycher Ben D.** | Residential exposure to agricultural pesticides and the risk of childhood cancer

*Institute of Social and Preventive Medicine, Universität Bern (UniBE), Bern*

CHF 351 418 | 36 months | [KFS-6225-08-2024](#)

## Health services research

**Cathomas Richard** | Oncological and functional follow-up after cystectomy and trimodal therapy (INFORMATORY)

*Onkologie, Kantonsspital Graubünden (KSGR), Chur*

CHF 313 777 | 48 months | [KFS-6065-02-2024](#)

**Cobos Munoz Daniel** | Enhancing palliative care in Lao PDR: addressing the unmet needs

*Epidemiology and Public Health, Schweizerisches Tropen- und Public Health-Institut (Swiss TPH), Allschwil*

CHF 276 606 | 36 months | [KFS-6082-02-2024](#)

**Maessen Maud** | The impact of care goals on costs of inpatient palliative care patients with cancer. Have we been comparing apples and oranges?

*University centre of palliative care, Inselspital Bern, Bern*

CHF 105 680 | 18 months | [KFS-6062-02-2024](#)

**Schwenkglens Matthias** | Pre-planned health economic analysis of SAKK 96/12: prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks – a non-inferiority phase III trial

*Department of Public Health, Universität Basel, Basel*

CHF 88 497 | 30 months | [KFS-6193-08-2024](#)

**Tolotti Angela** | Advanced Practice Nursing in an oncology palliative care setting and its effects on patient autonomy, engagement and interprofessional collaboration: an implementation mixed-method pre-post study

*Nursing research and development unit, Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona*

CHF 193 929 | 36 months | [KFS-6023-02-2024](#)

## Psychosocial research

**Sommer Grit** | Exploring trends of health-related quality of life after childhood cancer and its drivers/determinants: A longitudinal study

*Institute of Social and Preventive Medicine, Universität Bern (UniBE), Bern*

CHF 366 775 | 36 months | [KFS-6105-02-2024](#)

**Wünsch Alexander** | Empowering medical literacy in patients by pathology, oncology, onconursing and oncopsychology with explanation and rationalisation (EMPPO3WER): feasibility study with mixed methods

*Universitätsklinik für Medizinische Onkologie, Inselspital Bern, Bern*

CHF 286 408 | 36 months | [KFS-6151-08-2024](#)

## Fellowships

**Guedj Danaé** | Exploring and exploiting HPV-specific CD4 T cells for head and neck squamous cell cancer immunotherapy

*Département de pathologie et d'immunologie, Université de Genève (UNIGE), Genève 4*  
CHF 138 712 | 24 months | [MD-PhD-6133-02-2024](#)

**Peres Tobias** | Real world data of Nivolumab/Relatlimab in patients with melanoma brain metastasis

*Medical Oncology / Hematology, Kantonsspital St. Gallen (KSSG), St. Gallen*  
CHF 62 600 | 12 months | [KFS-6101-02-2024 BIL](#)

**Thavayogarah Tharshika** | Identifying the role of WRN in clonal haematopoiesis

*Department of Hematology and Oncology, Universitätsspital Zürich (USZ), Zürich*  
CHF 126 000 | 24 months | [KFS-6067-02-2024 BIL](#)

**Trepl Julia** | Deciphering lung cancer metastasis through clonal and microenvironmental analysis

*Medizinische Onkologie und Hämatologie, Universitätsspital Zürich (USZ), Zürich*  
CHF 125 600 | 24 months | [KFS-6220-08-2024 BIL](#)